Price Alert

BioNTech SE (BNTX)

NASDAQ: BNTX · Real-Time Price · USD

105.49

0.98 (0.94%)

At close: Oct 03, 2025, 3:59 PM

105.48

-0.01%

After-hours: Oct 03, 2025, 06:50 PM EDT

0.94% (1D)

Bid	104.56
Market Cap	25.36B
Revenue (ttm)	2.88B
Net Income (ttm)	-347.44M
EPS (ttm)	-1.68
PE Ratio (ttm)	-62.79
Forward PE	-25.06
Analyst	Buy
Dividends	n/a

Ask	105.49
Volume	524,263
Avg. Volume (20D)	880,201
Open	104.55
Previous Close	104.51
Day's Range	104.26 - 106.52
52-Week Range	81.20 - 129.27
Beta	1.46
Ex-Dividend Date	n/a

About BNTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BNTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BNTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

BioNTech SE is scheduled to release its earnings on Nov 3, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

-7.26%

Vaccine stocks are trading lower after a report in... Unlock content with Pro Subscription

3 weeks ago

-8.71%

BioNTech shares are trading lower. The company and Bristol Myers Squibb presented interim data from global randomized phase 2 trial evaluating Pumitamig an investigational bispecific antibody targeting PD-L1 X VEGF-A, plus chemotherapy in ES-SCLC patients.

News

4 days ago · seekingalpha.com

BioNTech SE, InstaDeep Ltd - Special Call

BioNTech SE, InstaDeep Ltd - Special Call Company Participants Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Karim Beguir Alexandre Laterre Bernardo Almeida Bora Guloglu Nicolas Lopez C...

4 days ago · fool.com

Why BioNTech Stock Jumped by Nearly 4% on Wednesday

Germany-based BioNTech (BNTX 3.64%) saw its U.S. listed stock enjoy a mini-pop on Wednesday, and for once this wasn't largely based on the Comirnaty COVID-19 vaccine it developed with Pfizer. Rather, ...

1 week ago · fool.com

Why BioNTech Stock Bumped Higher Today

A victory on the regulatory front and a bullish analyst move were the twin news items propelling BioNTech's (BNTX 2.52%) shares higher as the stock trading week began on Monday. The Germany-based biot...

2 weeks ago · youtube.com

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and ...

2 weeks ago · investors.com

The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut

The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters from Pfizer, Moderna and Novavax.

3 weeks ago · fool.com

Why BioNTech Stock Sank by More Than 7% Today

A star stock during the pandemic era wasn't shining so brightly on Friday. On a media report that the current presidential administration is preparing to link a set of fatalities to Covid vaccines, Bi...

3 weeks ago · marketwatch.com

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.

3 weeks ago · zacks.com

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.

3 weeks ago · benzinga.com

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BioNTech SE BNTX and Bristol Myers Squibb Co BMY shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCL...

3 weeks ago · reuters.com

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the G...

Load More News